Munich - Delayed Quote • EUR Atrium Ljungberg AB (A1A0.MU) Follow Add holdings 2.9480 +0.0280 +(0.96%) As of 8:13:50 AM GMT+2. Market Open. Related News Stock futures, US-China tensions, May jobs report: 3 Things US stock futures (ES=F, NQ=F, YM=F) dip in Monday's pre-market session after the S&P 500 (^GSPC) closed out its best May trading month since 1990. China has snapped back on President Trump's claims that the nation has violated its trade agreement with the US, now alleging the United States is in violation of its trade truce. The US Bureau of Labor Statistics (BLS) is due to release the May jobs report this Friday, June 6. To watch more expert insights and analysis on the latest market action, check out more Morning Brief here. Is UnitedHealth Group (NYSE:UNH) A Risky Investment? Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously... BMO upgrades Nucor on compelling valuation, upside from tariff Investing.com -- BMO Capital Markets upgraded Nucor Corp (NYSE:NUE) saying the stock currently trades at a "compelling" valuation, with long-term growth potential amid the recently announced U.S. steel tariffs.Nucor rating was bumped Outperform from Market Perform. Stocks to Watch Monday: Alphabet, Tesla, UnitedHealth, Steel Dynamics ↗️ Cleveland-Cliffs (CLF), Steel Dynamics (STLD): Shares of U.S. steelmakers surged in premarket trading after President Trump said he would double tariffs on steel and aluminum to 50%. ️↘️ Stellantis (STLA): Higher levies on imported metal could raise input prices for carmakers with U. Moderna's New COVID Vaccine Secures FDA-Clearance For Seniors, At-Risk Individuals The U.S. Food and Drug Administration (FDA) on Saturday approved Moderna, Inc.’s (NASDAQ:MRNA) mNexspike (mRNA-1283), a new vaccine against COVID-19, for all adults 65 and older and individuals aged 12-64 years with at least one or more underlying risk factor as defined by the Centers for Disease Control and Prevention (CDC). “The FDA approval of our third product, mNEXSPIKE...,” said Stéphane Bancel, Chief Executive Officer of Moderna. The FDA’s approval of mNEXSPIKE is based on results from a Lyra Says Phase 3 Trial of Nasal Implant for Chronic Rhinosinusitis Meets Endpoints Lyra Therapeutics (LYRA) said Monday that a phase 3 trial of LYR-210 bioabsorbable nasal implant met Are Hedge Funds Warming Up To Google Stock Amid Magnificent Seven Upheaval? Here's what fundamental and technical analysis says about Google stock as generative AI presents new opportunities and risks for GOOGL stock. 2 No-Brainer Growth Stocks to Buy in June While the major indices have flatlined this year, several emerging tech stocks have posted jaw-dropping gains in 2025. Growth investors have had to dig deeper in 2025. With the S&P 500 flat year to date amid President Trump's global trade reset and persistent inflation, the broad-market rally has stalled. Sanofi Expands Rare Immunology Portfolio With Blueprint Buyout Sanofi SA (NASDAQ:SNY) on Monday agreed to acquire Blueprint Medicines Corporation (NASDAQ:BPMC). The acquisition includes a rare immunology disease medicine, Ayvakit/Ayvakyt (avapritinib), approved in the U.S. and the EU, and a promising advanced and early-stage immunology pipeline. Ayvakit/Ayvakyt is the only approved medicine for advanced and indolent systemic mastocytosis (ASM & ISM), a rare immunology disease, which is characterized by the accumulation and activation of aberrant mast cells Bristol to Pay BioNTech Up to $11.1 Billion in Cancer Deal (Bloomberg) -- Bristol-Myers Squibb Co. will pay BioNTech SE as much as $11.1 billion to license a next-generation cancer drug, as competition intensifies in an area of oncology that seeks to harness the immune system to attack tumors.Most Read from BloombergBillionaire Steve Cohen Wants NY to Expand Taxpayer-Backed FerryWhere the Wild Children’s Museums AreNow With Colorful Blocks, Tirana’s Pyramid Represents a Changing AlbaniaThe Economic Benefits of Paying Workers to MoveNYC Congestion Toll B BioNTech soars 15% on cancer drug deal with Bristol Myers Investing.com -- Shares in BioNTech (NASDAQ:BNTX) soared sharply Monday after Bristol-Myers Squibb Company (NYSE:BMY) agreed to pay $1.5 billion upfront to collaborate with the German biotech firm on the development of an experimental cancer treatment, the U.S. pharmaceutical company announced on Monday. Applied Digital Announces 250MW AI Data Center Lease With CoreWeave in North Dakota DALLAS, June 02, 2025 (GLOBE NEWSWIRE) -- Applied Digital Corporation (Nasdaq: APLD), a designer, builder and operator of next-generation digital infrastructure for HPC applications, has entered into two approximately 15-year lease agreements with CoreWeave, the AI Hyperscaler™. Under the lease agreements, Applied Digital will deliver 250 megawatts (MW) of critical IT load to host CoreWeave's artificial intelligence (AI) and high-performance computing (HPC) infrastructure at its Ellendale, North Campbell Soup beats Q3 estimates, reaffirms guidance Investing.com -- Campbell Soup Company reported better-than-expected third quarter results on Monday, as the food giant benefited from its recent Sovos Brands acquisition and saw improved consumption across income groups. DraftKings stock drops on new Illinois betting tax Investing.com -- Shares of DraftKings (NASDAQ:DKNG) fell 5%, while Flutter saw a 3.3% decline following the announcement of new legislation in Illinois that introduces additional fees for online sportsbook operators. The market reacted negatively to the news that came as a surprise over the weekend, with Illinois passing its FY26 Budget, which incorporates an incremental fee structure targeting high-volume operators. Market Chatter: Alphabet, Amazon-Backed Anthropic Hits $3 Billion Annualized Revenue as Demand for AI Services Surges Alphabet (GOOGL) and Amazon (AMZN) backed Artificial intelligence developer Anthropic has reached $3 Tesla Stock Is Falling. Is It a ‘Sell the News’ Month? Tesla is set to launch its highly anticipated robotaxi service this month. Will that drive shares higher or will investors take profits now that the seminal event has arrived? Nebius Group announces private placement of $1 billion in aggregate principal amount of convertible notes AMSTERDAM, June 02, 2025--Nebius Group N.V. ("Nebius Group" or the "Company"; NASDAQ: NBIS), a leading AI infrastructure company, today announced that it has entered into definitive agreements for a private placement of senior unsecured convertible notes in an aggregate principal amount of $1 billion, in two tranches: $500,000,000 aggregate principal amount of 2.00% convertible notes due 2029 (the "2029 Notes"), and $500,000,000 aggregate principal amount of 3.00% convertible notes due 2031 (the BioNTech Sets Cancer-Drug Deal With Bristol Myers Squibb BioNTech and Bristol Myers Squibb have agreed to jointly develop and commercialize BioNTech’s BNT327 cancer-drug candidate in a deal potentially worth more than $11 billion to the German drugmaker. 5 Things to Know Before the Stock Market Opens News of the day for June 2, 2025 Tesla's European sales rout continues but new Model Y boosts Norway deliveries LONDON (Reuters) -Tesla's car sales fell sharply in several European markets including Sweden and Portugal in May, a fifth consecutive monthly decline that has been blamed on CEO Elon Musk's political activities and an outdated model lineup. However, Norway, where Tesla has started delivering revamped versions of its midsize SUV Model Y, provided a lone bright spot for the company as it prepares to roll out the refreshed vehicle in more European markets from this month. Performance Overview Trailing total returns as of 6/2/2025, which may include dividends or other distributions. Benchmark is OMX Stockholm 30 Index (^OMX) Return A1A0.MU OMX Stockholm 30 Index (^OMX) YTD +6.56% -0.09% 1-Year +6.56% -4.73% 3-Year +6.56% +19.53%